deltatrials
Completed PHASE2 NCT01289067

Utilizing A Genomic Sig for BRCAness to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for BRCAness: A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel

Sponsor: Prostate Cancer Foundation

Conditions Prostate Cancer
Interventions Satraplatin
Updated 10 times since 2017 Last updated: Jan 16, 2018 Started: Dec 31, 2010 Primary completion: May 31, 2013 Completion: May 31, 2013

This PHASE2 trial investigates Prostate Cancer and is currently completed. Prostate Cancer Foundation leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE2

  4. Feb 2017 — Mar 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Prostate Cancer Foundation
  • William K. Oh
Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States